# C_2021365EN.01000501.xml

| 10.9.2021 | EN | Official Journal of the European Union | C 365/5 |
| --- | --- | --- | --- |

10.9.2021

EN

Official Journal of the European Union

C 365/5

---

Prior notification of a concentration

(Case M.10452 — CPP Investments/FountainVest/

Langdi Pharmaceutical)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 365/04)

1.

This notification concerns the following undertakings:

| — | Canada Pension Plan Investment Board (‘CPP Investments’, Canada), |
| --- | --- |

—

Canada Pension Plan Investment Board (‘CPP Investments’, Canada),

| — | FountainVest Capital Partners GP4 Ltd. (‘FountainVest’, Cayman Islands), and |
| --- | --- |

—

FountainVest Capital Partners GP4 Ltd. (‘FountainVest’, Cayman Islands), and

| — | Beijing Zhendong Langdi Pharmaceutical Co., Ltd. And its subsidiaries (‘Langdi Pharmaceutical’, China). |
| --- | --- |

—

Beijing Zhendong Langdi Pharmaceutical Co., Ltd. And its subsidiaries (‘Langdi Pharmaceutical’, China).

CPP Investments and FountainVest acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Langdi Pharmaceutical.

The concentration is accomplished by way of purchase of shares.

2.

| — | CPP Investments is a professional investment management organisation that invests in public equities, private equities, real estate, infrastructure and fixed income instruments. |
| --- | --- |

—

CPP Investments is a professional investment management organisation that invests in public equities, private equities, real estate, infrastructure and fixed income instruments.

| — | FountainVest is an independent private equity firm. Sectors of focus include consumer, media & technology, healthcare, industrials, and financial services. |
| --- | --- |

—

FountainVest is an independent private equity firm. Sectors of focus include consumer, media & technology, healthcare, industrials, and financial services.

| — | Langdi Pharmaceutical is a pharmaceutical company mainly active in the production and supply of calcium supplements for children, pregnant and lactating women, menopausal women and elderly people, to help prevent and treat osteoporosis, which are registered as over-the-counter (OTC) products. |
| --- | --- |

—

Langdi Pharmaceutical is a pharmaceutical company mainly active in the production and supply of calcium supplements for children, pregnant and lactating women, menopausal women and elderly people, to help prevent and treat osteoporosis, which are registered as over-the-counter (OTC) products.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10452 — CPP Investments/FountainVest/Langdi Pharmaceutical

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---